home All News open_in_new Full Article

Inveready invierte en Atlas Molecular para avanzar en el tratamiento de enfermedades raras

La operación de financiación conseguida por la 'spin off' asciende a 3 millones de euros y servirá para impulsar el desarrollo clínico de la terapia para el tratamiento de la porfiria eritropoyética congénita (CEP), una enfermedad ultra rara sin tratamientos aprobados. Leer


today 63 h. ago attach_file Politics

attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics


ID: 986067130
Add Watch Country

arrow_drop_down